Breaking News

BioDuro to Develop COVID-19 Nanobody Therapeutic

Specialized COVID-19 team and technology assembled to accelerate discovery of new biologic

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioDuro, a global life sciences contract research and development organization, has initiated a COVID-19 nanobody therapeutic program, leveraging the company’s biologics discovery platform and a specialized COVID-19 dedicated team. The cornerstone of the effort includes screening more than 10 billion human synthetic antibodies generated using Artificial Intelligence (AI) computing and high-speed DNA mutagenesis technology.   BioDuro’s COVID-19 program relies on synthetic antibody technology, tar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters